<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy E Lotze, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald J Chadwick, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute disseminated encephalomyelitis (ADEM), also known as postinfectious encephalomyelitis, is a demyelinating disease of the central nervous system that typically presents as a monophasic disorder associated with multifocal neurologic symptoms and disability.
        </p>
        <p>
         This topic will review the treatment and prognosis of ADEM in children. Other aspects of ADEM are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of treatment for ADEM is high-dose intravenous glucocorticoids [
         <a href="#rid1">
          1,2
         </a>
         ]. Additional options include intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         and plasma exchange [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1157343148">
         <span class="h2">
          Empiric antibiotic treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with ADEM typically present with fever, meningeal signs, acute encephalopathy, and evidence of inflammation in blood and cerebrospinal fluid. Thus, it is reasonable to treat with broad-spectrum antibiotics and
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         until an infectious etiology is excluded. (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5977.html" rel="external">
          "Acute viral encephalitis in children: Treatment and prevention", section on 'Empiric acyclovir'
         </a>
         .)
        </p>
        <p>
         However, once ADEM is considered the most likely diagnosis, immunotherapy (most often intravenous high-dose glucocorticoids) should be started if it is not already being given.
        </p>
        <p class="headingAnchor" id="H1994995054">
         <span class="h2">
          Initial immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with ADEM, we recommend immunotherapy using either high-dose glucocorticoids, intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG), or plasma exchange. We suggest initial therapy with glucocorticoids rather than IVIG or plasma exchange, in line with most of limited published evidence and clinical experience. Glucocorticoids may be started at the time of the patient's presentation and can be used concurrently with antibiotics and
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         in consultation with an infectious disease specialist. Antibiotics and acyclovir can be discontinued when infection has been ruled out through medical judgement and/or test results. (See
         <a class="local">
          'Empiric antibiotic treatment'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H756417802">
         <span class="h2">
          Assessing response to initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with ADEM should be evaluated daily to determine whether they are improving with immune-modulating therapy. Clinical parameters can be used to monitor response. Resolution or clinically meaningful improvement of altered mental status (eg, coma, encephalopathy) and associated neurologic deficits (eg, cerebellar ataxia, hemiparesis, cranial neuropathies) suggests a good response to immunotherapy, whereas the lack of meaningful improvement or continued neurologic deterioration implies a poor response.
        </p>
        <p>
         While an immediate response is not expected, improvement should be evident within a few days of starting immunotherapy, in line with the usual five-day course of high-dose intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         treatment. Ongoing deterioration or the absence of meaningful improvement at five to seven days after starting treatment should signal the need for further treatment with a different immunotherapy, as discussed in the following section.
        </p>
        <p class="headingAnchor" id="H3021803320">
         <span class="h2">
          Inadequate response to acute therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our clinical experience, most patients do not require a second therapy. However, for children who do not have clinically significant improvement after five days of intravenous glucocorticoids (eg,
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         ), we treat with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         (2 g/kg given in divided doses over three days); plasma exchange (a total of six exchanges, one every other day) is an alternative that is most often used for patients with fulminant forms of ADEM and profound encephalopathy (eg, coma) who need intensive care unit management. For most children, we prefer IVIG over plasma exchange because of relative safety and ease of administration; it is also more widely available. (See
         <a class="local">
          'Intravenous immune globulin'
         </a>
         below.)
        </p>
        <p>
         For children with ADEM who have longitudinally extensive transverse myelitis and an inadequate response to initial glucocorticoid therapy, it is reasonable to treat with plasma exchange rather than
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         . (See
         <a class="local">
          'Plasma exchange'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H366030580">
         <span class="h2">
          Inadequate response to a second therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who have a poor response to initial treatment with intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         and no meaningful improvement within one week after completing a second-line therapy (either
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         or plasma exchange) should receive the alternate treatment (ie, IVIG after plasma exchange or vice versa). Plasma exchange halts any potential ongoing benefit of IVIG by removing it from the circulation, but the absence of a clinical response to IVIG raises concerns for poor prognosis and justifies the compromise entailed with using plasma exchange shortly after IVIG.
        </p>
        <p>
         Some experts additionally treat such patients with ongoing weekly intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         (30 mg/kg per dose) in the hope of improving their outcome.
        </p>
        <p class="headingAnchor" id="H3213358315">
         <span class="h2">
          Management of malignant edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some rare cases, fulminant ADEM or acute hemorrhagic leukoencephalitis (AHL) may progress to develop malignant, space-occupying brain edema with increased intracranial pressure and brain tissue shifts or herniation [
         <a href="#rid5">
          5
         </a>
         ]. This process can lead to neurologic deterioration with signs that typically include decreased arousal, pupillary changes, and worsening of motor responses. These neurologic signs are indicators of the need to intervene urgently with measures to treat brain edema.
        </p>
        <p>
         Standard medical therapy for worsening edema involves close monitoring for neurologic complications; and interventions to reduce intracerebral pressure such as elevation of the head of the bed, osmotic therapy, brief periods of hyperventilation as needed, and hemicraniectomy for patients with life-threatening cerebral edema [
         <a href="#rid6">
          6,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3457890712">
         <span class="h2">
          Treatment for relapsing disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with relapse of disease, we suggest intravenous glucocorticoids for acute management. There should be careful review of the initial diagnosis for such patients to determine if their relapse represents multiphasic ADEM (see
         <a class="local">
          'Relapses'
         </a>
         below) or another demyelinating syndrome such as myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, multiple sclerosis, or neuromyelitis optica spectrum disorder. (See
         <a class="medical medical_review" href="/z/d/html/6177.html" rel="external">
          "Differential diagnosis of acute central nervous system demyelination in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">
          "Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">
          "Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         If an alternative diagnosis is identified, then ongoing treatment should be specific to that disease. Many patients with a relapse of ADEM or with ADEM followed by optic neuritis will have an elevated MOG immunoglobulin G (IgG) antibody titer, and this would be an indication to initiate ongoing prophylactic maintenance therapy with monthly intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         or monthly
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         . Intravenous methylprednisolone is typically given as single a dose of 30 mg/kg each month and IVIG as a single dose of 1 gm/kg each month. The total duration of this therapy is individually determined and based upon tolerance and response, including the severity and sequela of prior attacks, recurrent attacks, the degree of persistence of MOG IgG antibody, and stability of repeat imaging studies. Most patients are treated for 12 to 24 months. Discontinuation of treatment requires ongoing close monitoring to assure true remission of disease. (See
         <a class="local">
          'Relapses'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1769269480">
         <span class="h1">
          IMMUNE-MODULATING THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effectiveness of immunotherapies (ie, glucocorticoids, intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         , and plasma exchange) for ADEM is supported by results from small observational studies. However, there are no randomized controlled trial data, and the optimal treatment has not been established.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         In several small observational studies, treatment of ADEM with intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         (10 to 30 mg/kg per day, maximum 1000 mg daily) or
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         (1 mg/kg per day) for three to five days, followed by oral glucocorticoid taper over four to six weeks, was associated with full recovery in approximately 60 to 90 percent of patients [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
         In the only study that compared these two treatments for ADEM, intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         (n = 21) was associated with a modestly better outcome, as measured by the median Expanded Disability Status Scale, compared with intravenous
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         (n = 25) [
         <a href="#rid10">
          10
         </a>
         ]. The strength of this result is limited by small patient numbers, lack of randomization, and lack of blinded treatment or assessment.
        </p>
        <p>
         Although the prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhagic variants of ADEM such as acute hemorrhagic leukoencephalitis (AHL) than for typical ADEM, a few case reports suggest that early high-dose glucocorticoid treatment may be associated with good recovery in children [
         <a href="#rid10">
          10,11
         </a>
         ] who have hemorrhagic variants of ADEM. (See
         <a class="local">
          'Prognosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Acute hemorrhagic leukoencephalitis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and duration
         </strong>
         – Although there is no consensus regarding glucocorticoid regimens, we use
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         (30 mg/kg per day, up to a maximum dose of 1000 mg per day) for five days. We use an oral
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         taper only in children who continue to show clinical symptoms after completion of the high dose intravenous glucocorticoid treatment. The prednisone taper is typically started at a lower initial dose compared with the intravenous regimen. We begin the taper with oral prednisone 1 mg/kg per day up to a maximum of 60 mg per day and then reduce the dose by 10 mg every five days to allow for a total tapering duration of four to six weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no convincing evidence that the use of a tapering oral glucocorticoid regimen, or its duration, influences outcome after intravenous glucocorticoid therapy. Two small observational studies reported higher relapse rates in children with ADEM who were treated with shorter (three weeks or less) compared with longer glucocorticoid tapers, but this finding was not statistically significant [
         <a href="#rid8">
          8,12
         </a>
         ]. In addition, the results from one of these studies [
         <a href="#rid12">
          12
         </a>
         ] were confounded by the inclusion of patients who had clinically isolated syndromes suggestive of multiple sclerosis. Such patients might have a higher relapse risk compared with those who meet all criteria for the diagnosis of ADEM.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The short-term use of high-dose glucocorticoid treatment is usually well tolerated. Potential complications include mental status changes, increased susceptibility to infection, and gastric disturbance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from small case series and case reports suggest that intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) is beneficial as rescue therapy in patients with ADEM who fail to respond to
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         [
         <a href="#rid13">
          13-16
         </a>
         ] or as initial therapy [
         <a href="#rid17">
          17
         </a>
         ]. Dosing of IVIG in these studies ranged from 1 to 2 g/kg, given either as a single dose or divided over three to five days [
         <a href="#rid13">
          13-15,17
         </a>
         ].
        </p>
        <p>
         No studies have compared
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         treatment with glucocorticoids or plasma exchange [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and duration
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         is typically initiated if there is no clinical improvement within seven days of completing
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         . Our preferred IVIG regimen is a total of 2 g/kg given in divided doses over three days (ie, 667 mg/kg daily for three days); other centers may divide the dose over five days (ie, 400 mg/kg daily for five days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse reactions with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         may include headache, nausea, fever, aseptic meningitis, rash, acute renal failure (mostly related to sucrose-containing products), and rarely hyperviscosity. Immunoglobulin A (IgA) deficiency can lead to anaphylaxis in patients treated with IVIG. These are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that plasma exchange is beneficial in children with ADEM who have a poor response to treatment with intravenous immunoglobulin and/or
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         [
         <a href="#rid18">
          18-21
         </a>
         ]. The largest series was retrospective and reported improvement following plasma exchange in six children with ADEM who did not respond to initial treatment with glucocorticoids followed by
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         In another retrospective study, plasma exchange demonstrated some benefit for patients with idiopathic transverse myelitis when used in combination with intravenous glucocorticoids. Therefore, it may be of particular benefit for patients with ADEM associated with myelopathy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and duration
         </strong>
         – Our preferred regimen is a total of six exchanges, one every other day, with each exchange consisting of 1 to 1.5 plasma volumes. Albumin is typically used as the replacement fluid. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The main complications of plasma exchange are hypotension, sepsis, and problems with intravenous access. (See
         <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          EXTENDED FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follow-up magnetic resonance imaging (MRI) shows complete or partial resolution of abnormalities in the majority of ADEM cases [
         <a href="#rid8">
          8,23,24
         </a>
         ]. However, residual gliosis and demyelination persist in some. Although no consensus exists, some experts suggest obtaining at least two additional MRIs after the initial MRI, over a period of at least five years from the initial episode of ADEM, to confirm the absence of new inflammatory demyelinating lesions [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Long-term clinical follow-up and sequential imaging by MRI are usually required to confirm the diagnosis of ADEM [
         <a href="#rid3">
          3
         </a>
         ]. The development of relapses with new lesions on MRI is not compatible with a diagnosis of monophasic ADEM, and suggests that the correct diagnosis is either multiphasic ADEM, multiple sclerosis, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, or neuromyelitis optica spectrum disorder, depending on the clinical and imaging features. (See
         <a class="local">
          'Multiphasic ADEM'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6177.html" rel="external">
          "Differential diagnosis of acute central nervous system demyelination in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">
          "Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis"
         </a>
         .)
        </p>
        <p>
         For patients with detectable anti-MOG antibody titers, repeat testing should be performed every six months for at least one year. Patients with persistently high titers should be closely observed clinically and have repeat imaging every 6 to 12 months. Anti-MOG antibodies, while not specific for ADEM, may have prognostic value, suggesting an increased risk for recurrent demyelinating disease other than multiple sclerosis. (See
         <a class="medical medical_review" href="/z/d/html/6177.html" rel="external">
          "Differential diagnosis of acute central nervous system demyelination in children", section on 'MOG antibody-associated disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H55051393">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2106375297">
         <span class="h2">
          Disability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with ADEM make a full recovery, usually slowly over four to six weeks, but a minority have persistent motor or cognitive impairments [
         <a href="#rid25">
          25
         </a>
         ]. At follow-up, approximately 60 to 90 percent have minimal or no neurologic deficits [
         <a href="#rid8">
          8-10,26-28
         </a>
         ]. One of the largest studies included 84 children from Argentina with ADEM [
         <a href="#rid10">
          10
         </a>
         ]. At a mean follow-up of 6.6 years, the neurologic examination was either normal or detected minor abnormalities but no associated disability in 75 children (89 percent). Residual deficits in the remaining children included mild to severe hemiparesis, mild paraparesis, partial epilepsy, reduced visual acuity, and cognitive impairment. Additional residual deficits, described in other studies, have included behavioral problems, minor gross motor abnormalities, and persistent limb paresthesia [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         The extent and site of lesions on the initial MRI do not predict the clinical outcome [
         <a href="#rid10">
          10,29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H47110541">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies of ADEM in children have reported no mortality [
         <a href="#rid4">
          4
         </a>
         ], but other studies have found that mortality of ADEM was approximately 3 percent [
         <a href="#rid30">
          30-33
         </a>
         ].
        </p>
        <p>
         The prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhage variants of ADEM, such as acute hemorrhagic leukoencephalitis (AHL), than for typical ADEM [
         <a href="#rid3">
          3
         </a>
         ]. Brain edema and subsequent death may occur within a week of the onset of encephalopathy in these uncommon variants. However, immunotherapy may be associated with improved outcome. (See
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Acute hemorrhagic leukoencephalitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2536296454">
         <span class="h2">
          Relapses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with ADEM have monophasic disease, with no recurrent clinical episodes or demyelination with long-term follow-up. However, one or more additional demyelinating events occur in up to 36 percent [
         <a href="#rid4">
          4
         </a>
         ]; seropositivity for anti-myelin oligodendrocyte glycoprotein (MOG) antibodies is associated with an increased risk for recurrent demyelinating disease other than multiple sclerosis. (See
         <a class="medical medical_review" href="/z/d/html/6177.html" rel="external">
          "Differential diagnosis of acute central nervous system demyelination in children", section on 'MOG antibody-associated disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1726870187">
         <span class="h3">
          Monophasic ADEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features of ADEM typically follow a monophasic disease course, although they can fluctuate in severity and evolve in the first three months following disease onset [
         <a href="#rid34">
          34
         </a>
         ]. Any new and fluctuating symptoms occurring within three months of the initial event are considered to be part of the same inciting event.
        </p>
        <p class="headingAnchor" id="H2783364914">
         <span class="h3">
          Multiphasic ADEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiphasic ADEM is defined as two episodes consistent with ADEM separated by at least three months, irrespective of glucocorticoid use, but not followed by any further events [
         <a href="#rid34">
          34
         </a>
         ]. The second ADEM event can involve either new or a re-emergence of prior neurologic symptoms, signs and magnetic resonance imaging (MRI) findings. By definition, both the first and second event must include a clinical presentation with encephalopathy. A second or additional attack that does not include encephalopathy and occurs three or more months after the first episode can be considered to either represent multiple sclerosis if the MRI findings meet the radiologic criteria for dissemination in space, or to represent MOG antibody-associated disease or neuromyelitis optica spectrum disorder if associated criteria are met.
        </p>
        <p class="headingAnchor" id="H649337973">
         <span class="h3">
          ADEM followed by optic neuritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some children, monophasic or multiphasic ADEM is followed by single or recurrent attacks of optic neuritis [
         <a href="#rid32">
          32,35,36
         </a>
         ]. This uncommon phenotype has been associated in all cases with high serum titers of anti-MOG antibodies, and represents one type of MOG antibody-associated disease.
        </p>
        <p class="headingAnchor" id="H3226857617">
         <span class="h3">
          Three or more relapses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapses beyond a second event are no longer consistent with ADEM, and indicate a chronic disorder such as multiple sclerosis, MOG antibody-associated disease, or neuromyelitis optica spectrum disorder [
         <a href="#rid34">
          34
         </a>
         ]. The initial ADEM event is considered the first attack of the chronic disease in this regard.
        </p>
        <p class="headingAnchor" id="H1414430046">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">
          "Society guideline links: Multiple sclerosis and related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children with acute disseminated encephalomyelitis (ADEM) typically present with fever, meningeal signs, acute encephalopathy, and evidence of inflammation in blood and cerebrospinal fluid. Thus, it is reasonable to treat with broad-spectrum antibiotics and
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         until an infectious etiology is excluded. (See
         <a class="local">
          'Empiric antibiotic treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with ADEM, we recommend immunotherapy using either glucocorticoids, intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG), or plasma exchange (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). We suggest initial therapy with high-dose glucocorticoids rather than IVIG or plasma exchange (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Our preferred regimen is intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         (30 mg/kg per day, up to a maximum dose of 1000 mg per day) for five days, followed by a four to six week oral
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         taper for those with residual symptoms after intravenous treatment. (See
         <a class="local">
          'Initial immunotherapy'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children who do not have clinically significant improvement after five days of intravenous glucocorticoids (eg,
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         ), we treat with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         (2 g/kg given in divided doses over three days); plasma exchange (a total of six exchanges, one every other day) is an alternative. (See
         <a class="local">
          'Inadequate response to acute therapy'
         </a>
         above and
         <a class="local">
          'Intravenous immune globulin'
         </a>
         above and
         <a class="local">
          'Plasma exchange'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with a poor response to initial intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         treatment and no meaningful improvement within one week after completing
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         therapy as a second therapy, it is reasonable to treat with plasma exchange. (See
         <a class="local">
          'Inadequate response to a second therapy'
         </a>
         above and
         <a class="local">
          'Intravenous immune globulin'
         </a>
         above and
         <a class="local">
          'Plasma exchange'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term follow-up is necessary to document recovery and to confirm the diagnosis of ADEM. (See
         <a class="local">
          'Extended follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most children with ADEM make a full recovery, usually slowly over four to six weeks. At follow-up, 60 to 90 percent have minimal or no neurologic deficits. Mortality of up to 3 percent has been reported in some studies. The prognosis for survival and recovery of neurologic function is worse for the hyperacute hemorrhage variants of ADEM, such as acute hemorrhagic leukoencephalitis (AHL), than for typical ADEM. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most children with ADEM have monophasic disease; any new and fluctuating symptoms occurring within three months of the initial event are considered to be part of the same event. The occurrence of relapses beyond three months suggests alternative diagnoses, such as multiphasic ADEM, multiple sclerosis, ADEM plus optic neuritis, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, or neuromyelitis optica spectrum disorder. (See
         <a class="local">
          'Relapses'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Alper G. Acute disseminated encephalomyelitis. J Child Neurol 2012; 27:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray MP, Gorelick MH. Acute Disseminated Encephalomyelitis. Pediatr Emerg Care 2016; 32:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007; 68:S23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole J, Evans E, Mwangi M, Mar S. Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol 2019; 100:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekula RF Jr, Jannetta PJ, Rodrigues B, et al. Acute disseminated encephalomyelitis: a report of two fulminant cases and review of literature. Neurol Neurochir Pol 2008; 42:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed AI, Eynon CA, Kinton L, et al. Decompressive craniectomy for acute disseminated encephalomyelitis. Neurocrit Care 2010; 13:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dombrowski KE, Mehta AI, Turner DA, McDonagh DL. Life-saving hemicraniectomy for fulminant acute disseminated encephalomyelitis. Br J Neurosurg 2011; 25:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 Pt 12:2407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosman NP, Gottlieb SM, Bernstein CA. Acute hemorrhagic leukoencephalitis: recovery and reversal of magnetic resonance imaging findings in a child. J Child Neurol 1997; 12:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anlar B, Basaran C, Kose G, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003; 34:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol 1995; 10:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999; 165:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahlas DJ, Miller SP, Guerin M, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000; 54:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadian J, Kirk E, Holliday K, et al. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Dev Med Child Neurol 2017; 59:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishikawa M, Ichiyama T, Hayashi T, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999; 21:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stricker RB, Miller RG, Kiprov DD. Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis. J Clin Apher 1992; 7:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestri P, Grosso S, Acquaviva A, Bernini M. Plasmapheresis in a child affected by acute disseminated encephalomyelitis. Brain Dev 2000; 22:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyazawa R, Hikima A, Takano Y, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Brain Dev 2001; 23:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khurana DS, Melvin JJ, Kothare SV, et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005; 116:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113 ( Pt 2):291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordan JI, Gomez-Anson B, Moseley IF, Miller DH. Long term MRI follow-up of patients with post infectious encephalomyelitis: evidence for a monophasic disease. J Neurol Sci 1999; 167:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iype M, Ts A, Kunju PM, et al. Factors Related to Long Term Motor, Behavioral, and Scholastic Outcome in Children with Acute Disseminated Encephalomyelitis. Pediatr Neurol 2018; 89:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110:e21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mar S, Lenox J, Benzinger T, et al. Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis. J Child Neurol 2010; 25:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beatty C, Bowler RA, Farooq O, et al. Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatr Neurol 2016; 57:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khong PL, Ho HK, Cheng PW, et al. Childhood acute disseminated encephalomyelitis: the role of brain and spinal cord MRI. Pediatr Radiol 2002; 32:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Absoud M, Lim MJ, Chong WK, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013; 19:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iype M, Kunju PAM, Saradakutty G, et al. Short term outcome of ADEM: Results from a retrospective cohort study from South India. Mult Scler Relat Disord 2017; 18:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Absoud M, Parslow RC, Wassmer E, et al. Severe acute disseminated encephalomyelitis: a paediatric intensive care population-based study. Mult Scler 2011; 17:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013; 19:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennes EM, Baumann M, Lechner C, Rostásy K. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Neuropediatrics 2018; 49:3.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6208 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914374" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27253358" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute Disseminated Encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17438235" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31371120" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19105115" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute disseminated encephalomyelitis: a report of two fulminant cases and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20711687" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Decompressive craniectomy for acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21344963" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Life-saving hemicraniectomy for fulminant acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099444" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11376179" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12391351" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9373802" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute hemorrhagic leukoencephalitis: recovery and reversal of magnetic resonance imaging findings in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12973660" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acute disseminated encephalomyelitis in children: outcome and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8576561" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute disseminated encephalomyelitis: response to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10426148" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10746613" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27900773" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10465150" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1299654" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10722965" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Plasmapheresis in a child affected by acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11578855" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Plasmapheresis in fulminant acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16061599" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17485649" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2328406" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10521553" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long term MRI follow-up of patients with post infectious encephalomyelitis: evidence for a monophasic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30409457" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Factors Related to Long Term Motor, Behavioral, and Scholastic Outcome in Children with Acute Disseminated Encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165620" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acute disseminated encephalomyelitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808990" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26996404" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11819066" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Childhood acute disseminated encephalomyelitis: the role of brain and spinal cord MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516794" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29141794" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Short term outcome of ADEM: Results from a retrospective cohort study from South India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28768844" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876155" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Severe acute disseminated encephalomyelitis: a paediatric intensive care population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23572237" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23128668" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28859212" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
